Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1065845 as Adjunctive Treatment in MDD
NCT06963021Phase 3Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing NBI-1065845 with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Day 56. Started May 2025; status: recruiting.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06963021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963021.